Platinum-based Drugs Market By Type (Cisplatin, Oxaliplatin, Carboplatin, and Other), By Application (Colorectal Cancer, Ovarian Cancer, Lung Cancer, and Other), and By Region, Trends, Analysis and Forecast till 2030

Platinum-based Drugs Market size accounted for USD 1473.95 Million in 2020 and is estimated to be USD 2245.91 Million by 2030 and is anticipated to register a CAGR of 4.3%.

Platinum-based drugs comprise organized complexes of platinum. They are chemotherapeutic agents, mainly utilized in the treatment of cancer. Platinum witnesses as cell damaging agent for some cancer treatments. About 10% to 20% of patients treated with chemotherapy receive platinum-based drugs. These drugs are used either alone or in combination with other drug treatments.

Growth in the prevalence of cancer

The increasing incidence of cancer is a major driving factor in the global platinum-based drugs market. As per the National Cancer Institute report, the number of new cancer cases per year is projected to increase to 23.6 million by 2030. Platinum-based cancer drugs market involves recent developments such as the development of analog platinum drugs including platinum carrier molecule complexes to boost targeted concentration of drugs in cancer tumors. According to the WHO report, cancer is the second dominating cause of death worldwide and estimated to an approximately 9.6 million deaths in 2018, including lung cancer with an estimated 2.09 million cases.

Conversely, drug-related side effects and resistance growth are the major limitations of this industry worldwide.

The global platinum-based drugs market is segmented based on type, application, and region.

On the basis of type, the global platinum-based drugs market is segmented into cisplatin, oxaliplatin, carboplatin, and other. On the basis of application, the target market is classified into colorectal cancer, ovarian cancer, lung cancer, and other.

Regional Insights:

On region the global platinum-based drugs market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America leads the global market in 2018 owing to growing incidence of cancer in the region, expansions in platinum-based drugs, and recent FDA approvals. Asia Pacific market is expand to grow at the highest CAGR due to rise in prevalence of diseases, increase in per capita income, improvement in health care infrastructure, and surge in awareness.

Segments Covered in the Report:

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest application trends and opportunities in each of the sub-segments from 2020 to 2030. For the purpose of this study, has segmented the global platinum-based drugs market report based on type, application, and region.

Global Platinum-based Drugs Market, By Type:

• Cisplatin
• Oxaliplatin
• Carboplatin
• Other

Global Platinum-based Drugs Market, By Application:

• Colorectal Cancer
• Ovarian Cancer
• Lung Cancer
• Other

Global Platinum-based Drugs Market, By Region:

• North America
  • Middle East & Africa
    • GCC
    • Israel
    • South Africa
    • Rest of Middle East & Africa
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Asia Pacific
    • China
    • India
    • Japan
    • South Korea
    • Rest of Asia Pacific
  • Europe
    • Germany
    • UK
    • France
    • Russia
    • Italy
    • Rest of Europe
  • U.S.
  • Canada

The key players operating the global platinum-based drugs market includes Pfizer, Inc., Ask-Pharma, Mylan N.V., Sanofi, Sun Pharmaceutical Industries Ltd., Accord Healthcare, Guizhou YiBai Pharmaceutical Co., Ltd., Novartis AG, Teva Pharmaceutical Industries Ltd., and Qilu Pharmaceutical Co., Ltd. Prominent key players are constantly involved in depending new treatment options to treat various diseases in order to provide safe and effective treatments for the patients. For instance, in February 2017, EMD Serono of Merck KGaA, Darmstadt, Germany, in the US and Canada, and Pfizer Inc. declared the US Food and Drug Administration (FDA) approval of Biologics License Application (BLA) for avelumab. Avelumab is used for the treatment of patients with locally advanced or metastatic urothelial carcinoma (mUC) with disease progression on or after platinum-based therapy.

• Pfizer, Inc.
• Ask-Pharma
• Mylan N.V.
• Sanofi
• Sun Pharmaceutical Industries Ltd.
• Accord Healthcare
• Guizhou YiBai Pharmaceutical Co., Ltd.
• Novartis AG
• Teva Pharmaceutical Industries Ltd.
• Qilu Pharmaceutical Co., Ltd.